All In Biotech

Drug Trial Radar · NCT07752875

A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

A Phase 1/2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Oct 31, 2032

Study completion Apr 30, 2033

Sponsor

Lead sponsor
LG ChemIndustry
Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation

Conditions

  • Ovarian Cancer
  • Small Cell Lung Cancer
  • Non Small Cell Lung Cancer
  • Colorectal Cancer
  • Esophageal Cancer
  • Breast Cancer
  • Endometrial Cancer
  • Head and Neck Cancer
  • Pancreatic Cancer
  • Locally Advanced Unresectable or Metastatic Solid Tumor

Interventions

  • LG00313112Drug

    LG00313112 will be administered orally once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to 21 days after treatment
  2. Phase 1: Frequency of treatment-emergent adverse events (TEAEs)Time frame: Up to 12 months after treatment initiation
  3. Phase 1: Frequency of serious adverse events (SAEs)Time frame: Up to 12 months after treatment initiation
  4. Phase 2: objective response rate (ORR)Time frame: Up to 12 months after treatment initiation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.